Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy
Journal for ImmunoTherapy of Cancer · 2023
DOI: 10.1136/jitc-2022-006267 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2023. Verfasst von Sandhya Sharma und 10 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Program in Translational Biology and Molecular Medicine, Baylor College of Medicine, Houston, Texas, USA. Hauptthemen laut MEDLINE: T-Lymphocytes, Herpesvirus 4, Human, Lymphoma, Immunological Memory Cells. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, American Society of Gene and Cell Therapy (ASGCT) - Career Development Award 2019, SCOR from Leukemia and Lymphoma Society.
Abstract (Originalsprache)
Background
The wider application of T cells targeting viral tumor-antigens via their native receptors is hampered by the failure to expand potent tumor-specific T cells from patients. Here, we examine reasons for and solutions to this failure, taking as our model the preparation of Epstein-Barr virus (EBV)-specific T cells (EBVSTs) for the treatment of EBV-positive lymphoma. EBVSTs could not be manufactured from almost one-third of patients, either because they failed to expand, or they expanded, but lacked EBV specificity. We identified an underlying cause of this problem and established a clinically feasible approach to overcome it.
Methods
CD45RO+CD45RA− memory compartment residing antigen-specific T cells were enriched by depleting CD45RA positive (+) peripheral blood mononuclear cells (PBMCs) that include naïve T cells, among other subsets, prior to EBV antigen stimulation. We then compared the phenotype, specificity, function and T-cell receptor (TCR) Vβ repertoire of EBVSTs expanded from unfractionated whole (W)-PBMCs and CD45RA-depleted (RAD)-PBMCs on day 16. To identify the CD45RA component that inhibited EBVST outgrowth, isolated CD45RA+ subsets were added back to RAD-PBMCs followed by expansion and characterization. The in vivo potency of W-EBVSTs and RAD-EBVSTs was compared in a murine xenograft model of autologous EBV+ lymphoma.
Results
Depletion of CD45RA+ PBMCs before antigen stimulation increased EBVST expansion, antigen-specificity and potency in vitro and in vivo. TCR sequencing revealed a selective outgrowth in RAD-EBVSTs of clonotypes that expanded poorly in W-EBVSTs. Inhibition of antigen-stimulated T cells by CD45RA+ PBMCs could be reproduced only by the naïve T-cell fraction, while CD45RA+ regulatory T cells, natural killer cells, stem cell memory and effector memory subsets lacked inhibitory activity. Crucially, CD45RA depletion of PBMCs from patients with lymphoma enabled the outgrowth of EBVSTs that failed to expand from W-PBMCs. This enhanced specificity extended to T cells specific for other viruses.
Conclusion
Our findings suggest that naïve T cells inhibit the outgrowth of antigen-stimulated memory T cells, highlighting the profound effects of intra-T-cell subset interactions. Having overcome our inability to generate EBVSTs from many patients with lymphoma, we have introduced CD45RA depletion into three clinical trials: NCT01555892 and NCT04288726 using autologous and allogeneic EBVSTs to treat lymphoma and NCT04013802 using multivirus-specific T cells to treat viral infections after hematopoietic stem cell transplantation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate Program in Translational Biology and Molecular Medicine, Baylor College of Medicine, Houston, Texas, USA.
- Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, and Houston Methodist Hospital, Houston, Texas, USA.
- Berlin Institute of Health (BIH) at Charité - Universitätsmedizin Berlin, BIH Center for Regenerative Therapies (BCRT), Charitéplatz 1, Berlin, Germany.
- Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas, USA.
- Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
- Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine, Houston, Texas, USA.
ORCID-Profile: Cliona M Rooney
Förderung
- NCI NIH HHS
- American Society of Gene and Cell Therapy (ASGCT) - Career Development Award 2019
- SCOR from Leukemia and Lymphoma Society
- Alex's Lemonade Stand Foundation for Childhood Cancer Reach Award
- NIH-NCI
- 1 SRA VSTs from Tessa Therapeutics, Singapore
- NIH-NLBI
- Baylor College of Medicine Comprehensive Cancer Training Program CPRIT fellowship
Zitieren
APA
Sharma, S., Woods, M., Mehta, N. U., Sauer, T., Parikh, K. S., Schmuck-Henneresse, M., Zhang, H., Mehta, B., Brenner, M. K., Heslop, H. E., & Rooney, C. M. (2023). Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2022-006267
Vancouver
Sharma S, Woods M, Mehta NU, Sauer T, Parikh KS, Schmuck-Henneresse M, et al. Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy. Journal for ImmunoTherapy of Cancer. 2023. doi:10.1136/jitc-2022-006267
BibTeX
@article{Sharma2023,
author = {Sharma, Sandhya and Woods, Mae and Mehta, Naren U and Sauer, Tim and Parikh, Kathan S and Schmuck-Henneresse, Michael and Zhang, Huimin and Mehta, Birju and Brenner, Malcolm K and Heslop, Helen E and Rooney, Cliona M},
title = {Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2023},
doi = {10.1136/jitc-2022-006267}
}
EUVIMED